Tilmanocept Pregnancy and Breastfeeding Warnings
Tilmanocept is also known as: Lymphoseek
Tilmanocept Pregnancy Warnings
Animal studies have not been conducted with this drug. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Comment: All radiopharmaceuticals, including this drug, have a potential to cause fetal harm.
Tilmanocept Breastfeeding Warnings
Use should be avoided.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comment: Discard breast milk for at least 60 hours (ten half-lives) after administration of this drug.
See also
References for pregnancy information
- "Product Information. Lymphoseek (tilmanocept)." Navidea Biopharmaceuticals (2013):
References for breastfeeding information
- "Product Information. Lymphoseek (tilmanocept)." Navidea Biopharmaceuticals (2013):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
